{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T22:29:51Z","timestamp":1793312991165,"version":"4.5.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,2,2]],"date-time":"2024-02-02T00:00:00Z","timestamp":1706832000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,2]],"date-time":"2024-02-02T00:00:00Z","timestamp":1706832000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Medical and Health Technology Development Program of Shandong Province","award":["No. 202011000934"],"award-info":[{"award-number":["No. 202011000934"]}]},{"name":"Medical and Health Technology Development Program of Shandong Province","award":["No. 202011000934"],"award-info":[{"award-number":["No. 202011000934"]}]},{"name":"Transfusion Medical Equipment Technology Committee of the Chinese Medical Equipment Association","award":["XS2020-2"],"award-info":[{"award-number":["XS2020-2"]}]},{"name":"Shandong Province Humanities and Social Science Project","award":["2021-ZXJK-24"],"award-info":[{"award-number":["2021-ZXJK-24"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>In China, according to the \u2018Technical Operating Procedures for Blood Stations (2019 Edition),\u2019 blood stations are authorized to utilize Chemiluminescence Immunoassay (CLIA) to detect pathogen markers linked with transfusion-transmissible infections. However, currently, there is no approved CLIA reagent for the screening of blood-borne diseases in China, specifically for the detection of Hepatitis B surface antigen. The objective of this research project is to conduct a comprehensive evaluation of the performance of the Wantai Chemiluminescent Microparticle Hepatitis B surface antigen reagent. This study evaluates the performance of the Wantai Chemiluminescent Microparticle Immunoassay (CMIA) on the Wan200\u2009+\u2009analyzer in screening for Hepatitis B Surface Antigen (HBsAg) in blood samples. The clinical trial component of this evaluation is included as part of the documentation submitted to the National Medical Products Administration (NMPA) of China for the approval of blood screening reagents. The evaluation plan of this study encompasses two main components: clinical trials and performance assessment. We adopted a controlled trial design, utilizing the WanTai Chemiluminescent Microparticle Immunoassay (CMIA) on the Wan200\u2009+\u2009analyzer and the Enzyme-Linked Immunosorbent Assay (ELISA) to screen for Hepatitis B Surface Antigen (HBsAg) in routine blood donor samples and reference serum panel samples. To ensure the accuracy of the screening, we additionally employed Abbott's ELISA reagents and HBV DNA for validation. The assessment primarily focused on key performance indicators such as sensitivity, specificity, and analytical sensitivity. Moreover, this clinical trial data has been included as part of the submission to China's National Medical Products Administration (NMPA). In the clinical trials of this study, a total of 10,470 blood donor samples underwent simultaneous testing using both CMIA and ELISA methods. Across two clinical trials, there was remarkable concordance between CMIA and the two ELISA reagents, with Kappa values exceeding 0.82. Among the 269 samples that were double-reactive in the enzyme immunoassay (ELISA) tests, CMIA exhibited a 100% reactivity detection rate. However, CMIA produced 14 and 6 false-positive results in the respective clinical trials, resulting in specificities of 99.73% and 99.89%. In contrast, the specificities for Wantai ELISA and Xin Chuang ELISA were both greater than 99.94%.When testing samples in the gray zone serum plates, CMIA's detection limit significantly exceeded that of the two ELISA assays. CMIA had a detection cutoff of 0.05\u00a0IU\/mL, while the two ELISA reagents had cutoffs of 0.1\u00a0IU\/mL and 0.09\u00a0IU\/mL, respectively. CMIA's detection limits for the adr and adw subtypes were 0.05\u00a0IU\/mL, and for the ay subtype, it was 0.1 U\/mL. The detection limit for 10 HBV mutant samples was 0.5 U\/mL. In 165 cases where ELISA tested negative but HBV DNA tested positive, CMIA detected 5 HBsAg-positive samples. This study evaluated the performance of the Wantai CMIA in screening for HBsAg among blood donors. The results demonstrate outstanding performance of CMIA in both clinical trials and performance assessments, detecting all true positive samples with a sensitivity of 100%. It exhibits excellent concordance with the two ELISA assays. Of particular note is its superiority in early detection of HBsAg in the screening of early-stage hepatitis B infections, reducing the window period compared to ELISA. CMIA achieves a specificity exceeding 99.73% for negative blood donors, aligning with the European Union's standards for blood screening assay specificity. In summary, Wantai's CMIA displays high sensitivity and specificity in blood donor screening, making it suitable for screening blood donors in China.<\/jats:p>","DOI":"10.1038\/s41598-024-51910-1","type":"journal-article","created":{"date-parts":[[2024,2,2]],"date-time":"2024-02-02T17:02:32Z","timestamp":1706893352000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Clinical trial and performance evaluation of the Wantai HBsAg (CMIA) diagnostic kit for screening blood donors in China"],"prefix":"10.1038","volume":"14","author":[{"given":"Jianfeng","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengtian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dandan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,2]]},"reference":[{"key":"51910_CR1","unstructured":"WHO, Hepatitis B, (2023)."},{"key":"51910_CR2","unstructured":"I. WHO, Global hepatitis report, 2017 [Internet], World Health Organization (2017)."},{"key":"51910_CR3","unstructured":"N.H.C.o. China, Technical Operating Procedures for Blood Stations (2019 Edition), April 2019."},{"issue":"2","key":"51910_CR4","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.tmrv.2020.02.001","volume":"34","author":"R Dodd","year":"2020","unstructured":"Dodd, R. et al. Screening blood donors for HIV, HCV, and HBV at the American Red Cross: 10-year trends in prevalence, incidence, and residual risk, 2007 to 2016. Transfus. Med. Rev. 34(2), 81\u201393 (2020).","journal-title":"Transfus. Med. Rev."},{"issue":"2","key":"51910_CR5","volume":"61","author":"P Arcot","year":"2022","unstructured":"Arcot, P. et al. Comparative evaluation of ADVIA Centaur\u00ae XP chemiluminescence system for screening of HBV, HCV, HIV and syphilis in Indian blood donors. Transfus. Apheresis Sci.: Off. J. World Apheresis Assoc.: Off. J. Eur. Soc. Haemapheresis 61(2), 103318 (2022).","journal-title":"Transfus. Apheresis Sci.: Off. J. World Apheresis Assoc.: Off. J. Eur. Soc. Haemapheresis"},{"issue":"2","key":"51910_CR6","doi-asserted-by":"publisher","first-page":"285","DOI":"10.55519\/JAMC-02-11600","volume":"35","author":"R Irshad","year":"2023","unstructured":"Irshad, R., Farooq, U., Shah, T., Gul, A. & Badshah, A. Hepatitis B C and hiv exposure on Nat and Clia blood examination methods at regional blood centre Abbottabad. J. Ayub Med. College, Abbottabad: JAMC 35(2), 285\u2013287 (2023).","journal-title":"J. Ayub Med. College, Abbottabad: JAMC"},{"key":"51910_CR7","unstructured":"E. Commission, Directive 98\/79\/EC of the European Parliament and of the Council of 27 October 1998 on in vitro diagnostic medical devices. Off. J. Eur. Commun. 331, 1-37 (1998)."},{"issue":"2","key":"51910_CR8","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1111\/vox.12259","volume":"109","author":"M Schmidt","year":"2015","unstructured":"Schmidt, M. et al. Head-to-head comparison between two screening systems for HBsAG, anti-HBc, anti-HCV and HIV combination immunoassays in an international, multicentre evaluation study. Vox Sanguinis 109(2), 114\u2013121 (2015).","journal-title":"Vox Sanguinis"},{"issue":"11","key":"51910_CR9","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1128\/CVI.00529-14","volume":"21","author":"X Cheng","year":"2014","unstructured":"Cheng, X. et al. Comparison of three luminescent immunoassays for hepatitis B virus surface antigen quantification during the natural history of chronic hepatitis B virus infection. Clin. Vacc. Immunol.: CVI 21(11), 1521\u20131527 (2014).","journal-title":"Clin. Vacc. Immunol.: CVI"},{"issue":"3","key":"51910_CR10","doi-asserted-by":"publisher","first-page":"443","DOI":"10.3390\/medicina59030443","volume":"59","author":"J Lee","year":"2023","unstructured":"Lee, J., Lee, S. Y., Cho, Y. G., Kim, D. S. & Park, J. Accuracy validation of the elecsys HBsAg II quant assay and its utility in resolving equivocal qualitative HBsAg results. Medicina 59(3), 443 (2023).","journal-title":"Medicina"},{"issue":"9","key":"51910_CR11","doi-asserted-by":"publisher","first-page":"606","DOI":"10.21037\/atm.2020.02.59","volume":"8","author":"R Yang","year":"2020","unstructured":"Yang, R. et al. A hook-effect-free homogeneous light-initiated chemiluminescence assay: is it reliable for screening and the quantification of the hepatitis B surface antigen?. Annals Trans. Med. 8(9), 606 (2020).","journal-title":"Annals Trans. Med."},{"key":"51910_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jviromet.2021.114112","volume":"292","author":"F Jiang","year":"2021","unstructured":"Jiang, F. et al. A study of performance evaluation of cobas e 801 infectious diseases panel. J. Virol. Methods 292, 114112 (2021).","journal-title":"J. Virol. Methods"},{"issue":"6","key":"51910_CR13","first-page":"578","volume":"38","author":"J Ryu","year":"2018","unstructured":"Ryu, J. et al. Development of a rapid automated fluorescent lateral flow immunoassay to detect hepatitis B surface antigen (HBsAg). Antibody HBsAg, Antibody Hepatitis C, Annals Lab. Med. 38(6), 578\u2013584 (2018).","journal-title":"Antibody HBsAg, Antibody Hepatitis C, Annals Lab. Med."},{"issue":"1","key":"51910_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1423-0410.2006.00773.x","volume":"91","author":"L Comanor","year":"2006","unstructured":"Comanor, L. & Holland, P. Hepatitis B virus blood screening: unfinished agendas. Vox Sanguinis 91(1), 1\u201312 (2006).","journal-title":"Vox Sanguinis"},{"issue":"1","key":"51910_CR15","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s12879-020-05747-4","volume":"21","author":"X Ye","year":"2021","unstructured":"Ye, X. et al. Molecular characteristics of HBV infection among blood donors tested HBsAg reactive in a single ELISA test in southern China. BMC Infect. Dis. 21(1), 83 (2021).","journal-title":"BMC Infect. Dis."},{"issue":"10","key":"51910_CR16","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1111\/jvh.12915","volume":"25","author":"M Gencay","year":"2018","unstructured":"Gencay, M. et al. Detection of in vivo hepatitis B virus surface antigen mutations-A comparison of four routine screening assays. J. Viral Hepatitis 25(10), 1132\u20131138 (2018).","journal-title":"J. Viral Hepatitis"},{"key":"51910_CR17","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.jcv.2018.04.005","volume":"103","author":"H Kim","year":"2018","unstructured":"Kim, H. et al. Frequency of hepatitis B surface antigen variants (HBsAg) in hepatitis B virus genotype B and C infected East- and Southeast Asian patients: Detection by the Elecsys HBsAg II assay. J. Clin. Virol.: Off. Pub. Pan Am. Soc. Clin. Virol 103, 48\u201356 (2018).","journal-title":"J. Clin. Virol.: Off. Pub. Pan Am. Soc. Clin. Virol"},{"key":"51910_CR18","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.jcv.2018.01.011","volume":"101","author":"M Gencay","year":"2018","unstructured":"Gencay, M. et al. Substantial variation in the hepatitis B surface antigen (HBsAg) in hepatitis B virus (HBV)-positive patients from South Africa: Reliable detection of HBV by the Elecsys HBsAg II assay. J. Clin. Virol.: Off. Pub. Pan Am. Soc. Clin. Virol. 101, 38\u201343 (2018).","journal-title":"J. Clin. Virol.: Off. Pub. Pan Am. Soc. Clin. Virol."},{"issue":"3","key":"51910_CR19","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.diagmicrobio.2016.04.004","volume":"85","author":"C Osiowy","year":"2016","unstructured":"Osiowy, C., Kowalec, K. & Giles, E. Discordant diagnostic results due to a hepatitis B virus T123A HBsAg mutant. Diagn. Microbiol. Infect. Dis. 85(3), 328\u2013333 (2016).","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"51910_CR20","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jviromet.2015.11.016","volume":"228","author":"R Yang","year":"2016","unstructured":"Yang, R. et al. The Lumipulse G HBsAg-Quant assay for screening and quantification of the hepatitis B surface antigen. J. Virol. Methods 228, 39\u201347 (2016).","journal-title":"J. Virol. Methods"},{"issue":"2","key":"51910_CR21","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1128\/CVI.05454-11","volume":"19","author":"S Maylin","year":"2012","unstructured":"Maylin, S. et al. Comparison between Elecsys HBsAg II and architect HBsAg QT assays for quantification of hepatitis B surface antigen among patients coinfected with HIV and hepatitis B virus. Clin. Vacc. Immunol.: CVI 19(2), 242\u2013248 (2012).","journal-title":"Clin. Vacc. Immunol.: CVI"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-51910-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-51910-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-51910-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,2]],"date-time":"2024-02-02T17:11:25Z","timestamp":1706893885000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-51910-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,2]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["51910"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-51910-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,2]]},"assertion":[{"value":"25 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1891"}}